


KIDNEY

VIRTUAL CONFERENCE

2021



Andrew W. Steele,
MD, FRCPC
CHAIR
Queen's University,
Kingston, ON

FACULTY



Christopher T. M. Chan,
MD, FRCPC
University of Toronto,
Toronto, ON




David Z. I. Cherney,
MD CM, PhD, FRCPC
University of Toronto,
Toronto, ON



Hiddo J. Lambers Heerspink,
MD, MSc, CCPE
University Medical Centre Groningen,
Groningen, Netherlands




Lawrence A. Leiter,
MD, FRCPC, FACP, FACE, FAHA,
FACC
University of Toronto,
Toronto, ON




Adeera Levin,
MD, FRCPC, CM
University of British Columbia,
Vancouver, BC




Peter J. Lin,
MD, CCFP
Canadian Heart Research Centre,
Toronto, ON




Louise Moist,
MD, MSc, CCPE, FRCPC
Western University,
London, ON




Vlado Perkovic,
MBBS, PhD, FASN, FRACP
University of New South Wales,
Sydney, NSW, Australia



Elizabeth Swiggum,
MD, FRCPC
University of British Columbia,
Victoria, BC



Navdeep Tangri,
MD, PhD, FRCPC
University of Manitoba,
Winnipeg, MB



Subodh Verma,
MD, PhD, FRCSC, FAHA
University of Toronto,
Toronto, ON



Michael Walsh,
MD, MSc, PhD, FRCPC
McMaster University,
Hamilton, ON



Jordan J Weinstein,
MD, FRCPC
University of Toronto,
Toronto, ON

Saturday, November 20th, 2021 | 10:00 h - 15:35 h EST

AGENDA * ALL TIMES ARE EST

10:00	Opening Remarks	Dr. Andrew Steele
10:10	New from KDIGO: Diabetes management in CKD	Dr. Christopher Chan
10:25	Vascular protection in CKD: Role of dual pathway inhibition	Dr. Subodh Verma
10:40	Cardio-renal connections	Dr. Jordan Weinstein
10:55	Plenary Dealing with hyperkalemia: why and how?	Dr. Louise Moist
11:20	The latest on lipid management in CKD	Dr. Lawrence Leiter
11:35	Q&A	
12:00	Break	
12:10	Biomarker panels in CKD	Dr. Hiddo Lambers Heerspink
12:25	MRAs in kidney protection and beyond	Dr. David Cherney
12:40	ARNIs: What are the opportunities in CKD?	Dr. Elizabeth Swiggum
12:55	SGLT2i for the prevention and treatment of kidney disease	Dr. Adeera Levin
13:10	Plenary HIF stabilizers: Looking into the future of anemia in CKD	Dr. Andrew Steele
13:35	GLP-1RAs: What is their role in CKD?	Dr. Vlado Perkovic
13:50	Q&A	
14:20	Break	
14:30	Staging, assessing, and referring the Kidney Patient	Dr. Navdeep Tangri
14:45	Remote care tips for the primary care practitioner	Dr. Peter Lin
15:00	Kidney trials coming over the horizon	Dr. Michael Walsh
15:15	Q&A	
15:35	Closing Remarks	Dr. Andrew Steele

LEARNING OBJECTIVES

At the conclusion of this program, attendees will be able to:

- Communicate the latest recommendations on managing kidney disease in the absence and presence of cardiac and vascular disease
- Explain how to assess risk and share the care of individuals with kidney disease
- Integrate and prioritize the emerging therapies for preventing and treating kidney disease

To register : www.Kidney2021.com

This program has been supported by educational grants from:
Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim/Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Otsuka